The problem of infection with viral hepatitis C is relevant nowadays. Despite the fact that scientists are still searching for new methods of treating this infectious disease, the main problems are complications that develop over the years in patients with hepatitis C. Fibrosis, cirrhosis, portal hypertension, liver failure, hepatocellular carcinoma, and different extrahepatic manifestations are the main causes of death. Even complete elimination of the virus after direct antiviral therapy does not stop developing of complications which effect on life expectancy. We cannot speak about morbidity because of the fact that viral hepatitis C is most often diagnosed at the stage of complications. All this is due to the asymptomatic, chronic development of this disease. We still diagnose complications from viral hepatitis C, but the infection could have happened 10 years ago. Human immunodeficiency virus is frequently found in patients with viral hepatitis C, which is most often directly related to the features of the mechanism of infection and transmission routes. The presence of untreated human immunodeficiency virus is a poor prognostic sign. This co-infection can affect the rate of development of complications and the general severity of the disease. Prevalence rate are still high, despite the development of various preventive measures to reduce infection with the listed above viruses, such as the free distribution of disposable syringes, barrier contraceptives, widespread promotion of a healthy lifestyle, informing the population about the danger of infection, etc. The lack of reliable and high-quality statistical information on the prevalence of viral hepatitis, both monoinfection and in association with human immunodeficiency virus is very important issue in Ukraine. There is also a small amount of data about the dominance of certain genotypes in different parts of our country. This absence information interferes with a clear understanding of the leading routes of transmission of infection and a targeted impact on them. There are also no clear screening programs for groups of risk. There are problems with clear control over patients, especially over those who have successfully completed antiviral therapy. This category of patients disappears from the control of medical workers. They often do not know that the absence of the virus in the blood still leaves a high risk of developing cirrhosis of the liver and other complications, because the liver was previously compromised. This once again proves the importance of dispensary observation of all treated patients, not depending on their response to therapy

Keywords: hepatitis C virus, liver cirrhosis, hepatocellular carcinoma, liver fibrosis, HIV

Full text: PDF (Rus) 357K

1. Globalnye prakticheskie rekomendatsii Vsemirnoy Gastroenterologicheskoy Organizatsii. Diagnoz, vedenie i profilaktika Gepatita С [Global practice guideline. Diagnosis, management and prevention of Hepatitis C]. World Gastroenterology Organisatio. 2017; 1: 38. [Russian]
2. Cost of treatment for Hepatitis C virus infection in Ukraine. [Internet]. EQUIP POLICY REPORT AUGUST 2019. 2019. Available from: https://sites.bu.edu/hiv/files/2019/08/EQUIP-Ukraine-cost-report-2019-08-06-final.pdf
3. Lledó GM, Carrasco I, Benítez-Gutiérrez LM, Arias A, Royuela A, Requena S, et al. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS. 2018; 32(16): 2347-2352. https://doi.org/10.1097/QAD.0000000000001966 PMid:30096074
4. Zou S, Tepper M, Saadany S El. Prediction of hepatitis C burden in Canada. Can J Gastroenterol. 2000; 14(7): 575-580. https://doi.org/10.1155/2000/642707 PMid:10978943
5. Palitzsch K D, Hottenträger B, Schlottmann K, Frick E, Holstege A, Schölmerich J, et al. Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol. 1999 Nov; 11(11): 1215-20. https://doi.org/10.1097/00042737-199911000-00005 PMid:10563529
6. Qureshi H, Bile K M, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. EMHJ. 2010; 16: 15-23. https://doi.org/10.26719/2010.16.Supp.15
7. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000 Mar 11; 355(9207): 887-91. doi: 10.1016/s0140-6736(99)06527-7 https://doi.org/10.1016/S0140-6736(99)06527-7
8. Chen S L, Morgan T R. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2): 47-52. doi: 10.7150/ijms.3.47 https://doi.org/10.7150/ijms.3.47 PMid:16614742 PMCid:PMC1415841
9. Khokhlova ON, Serebrovskaya LV, Karandashova IV, Chulanov VP, Reyzis AR. Novyy prognosticheskiy test effektivnosti protivovirusnoy terapii HCV i ego sravnitelnaya otsenka s opredeleniem geneticheskogo polimorfizma IL28B [A new prognostic test of the effectiveness of antiviral therapy for CHC and its comparative assessment with detection of IL28B gene polymorphism]. Infektsionnye bolezni. 2017; 15(1): 10-15. [Russian] https://doi.org/10.20953/1729-9225-2017-1-10-15
10. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV HBV international panel. AIDS. 2008; 22(12): 1399-1410. https://doi.org/10.1097/QAD.0b013e3282f8b46f PMid:18614862
11. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Research. 2010; 85: 303-315. https://doi.org/10.1016/j.antiviral.2009.10.021 PMid:19887087
12. Kosagovskaya II, Kosagovskaya II, Volchkova EV. Mediko-sotsialnye aspekty virusnykh gepatitov s parenteralnym putem peredachi [The medico-social aspects of viral hepatitides with the parenteral way of transmission]. Epidemiologiya i infektsionnye bolezni. 2013; 1: 28-39. [Russian]
13. Golubovska OA. Epidemiologiya ta pryrodnyi perebig gepatytu C [Epidemiology and Natural History of Hepatitis C Virus]. Klinichna endokrynologiya ta endokrynna khirurgiya. 2008; 4(25): 48-51. [Ukrainian]
14. Over 5% of Ukrainians are infected with hepatitis C [Internet]. 2016. Available from: http://aph.org.ua/en/news/over-5-of-ukrainians-are-infected-with-hepatitis-c/
15. Islam Z. Viral hepatitis control program country model Ukraine. [Internet]. 2018. Available from: http://regist2.virology-education.com/presentations/2018/4CEE/05_Islam.pdf
16. Shevchenko TM, Shcherbynina MB, Latsinska SA, Diklenko TV. Suchasni epidemiologichni tendentsiyi rozvytku HCV-infektsiyi v Ukraini [Recent epidemiological trends in HCV-infection in Ukraine]. Regul Mech Biosyst. 2017; 8(2): 210-216. [Ukrainian] https://doi.org/10.15421/021733
17. Mikhaylov MI, Malinnikova EYu, Potemkin IA, Kozhanova TV, Isaeva OV, Ilchenko LYu, et al. Epidemiologiya virusnykh gepatitov [Epidemiology of viral hepatitis]. Zhurn mikrobiol. 2013; 1: 78-85. [Russian]
18. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection. 2011; 17(2): 107-115. https://doi.org/10.1111/j.1469-0691.2010.03432.x PMid:21091831
19. Fazylov VKh. Etiologicheskie i patogeneticheskie aspekty diagnostiki i lecheniya virusnykh gepatitvo [Etiological and pathogenetic aspects of diagnosis and treatment of viral hepatitides]. Kazanskiy meditsinskiy zhurnal. 2013; 6: 785-792. [Russian] https://doi.org/10.17816/KMJ1791
20. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006 Apr 1; 3(2): 47-52. https://doi.org/10.7150/ijms.3.47 PMid:16614742 PMCid:PMC1415841
21. Bakulin IG. Aktualnye voprosy protivovirusnoy terapii khronicheskikh gepatitov B i C [Actual questions of antiviral therapy for chronic hepatitis B and C]. Eksperimentalnaya i kinicheskaya gastroenterologiya. 2010; 5: 3-9. [Russian]
22. Di Bisceglie A. M. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26(3): 34S-38S. https://doi.org/10.1002/hep.510260706 PMid:9305661
23. Kim NJ, Magee C, Cummings C, Park H, Khalili M. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatology Communications. 2018; 2(10): 1274-1283. https://doi.org/10.1002/hep4.1246 PMid:30288480 PMCid:PMC6167066
24. Carter M. Severe fibrosis improves in most people after hepatitis C cure but persists in a quarter. [Internet]. 2018. Available from: https://www.aidsmap.com/news/feb-2018/severe-fibrosis-improves-most-people-after-hepatitis-c-cure-persists-quarter
25. Lybeck C, Brenndörfer ED, Sällberg M, Montgomery SM, Aleman S, Duberg AS. Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. European Journal of Gastroenterology & Hepatology. 2019; 31(4): 506-513. https://doi.org/10.1097/MEG.0000000000001316 PMid:30461522 PMCid:PMC6416012
26. Baykova TA. Mnogoobrazie vnepechenochnykh proyavleniy khronicheskikh virusnykh gepatitov B i C, obshchie printsipy lecheniya [A variety of extrahepatic manifestations of chronic viral hepatitis B and C: basic treatment principles]. Terapevticheskiy arkhiv. 2013; 85(4): 106-110. [Russian]
27. Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifestations of chronic HCV infection. J Gastrointestin Liver Dis. 2007; 16(1): 65-73.
28. Cavalheiro Nde P, Filgueiras TC, Melo CE, Morimitsu SR, de Araújo ES, Tengan FM, et al. Detection of HCV by PCR in serum and PBMC of patients with hepatitis C after treatment. Braz J Infect Dis. 2007; 11(5): 471-474. https://doi.org/10.1590/S1413-86702007000500006 PMid:17962872
29. Pugnale P, Latorre P, Rossi C, Crovatto K, Pazienza V, Gottardi AD, et al. Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells. J Virol Methods. 2006; 133(2): 195-204. https://doi.org/10.1016/j.jviromet.2005.11.007 PMid:16384611
30. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59(1): 318-327. https://doi.org/10.1002/hep.26744 PMid:24115039 PMCid:PMC4063340
31. Sharara A, Hunt C, Hamilton J. Hepatitis C. [Internet]. 1996. Available from: https://www.mediasphera.ru/journals/mjmp/97/2/2-97-21.htm
32. Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol. 2015; 53(3): 967-972. https://doi.org/10.1128/JCM.02831-14 PMid:25520447 PMCid:PMC4390628
33. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl): S45-S57. https://doi.org/10.1016/j.jhep.2014.07.027 PMid:25086286
34. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016; 22(34): 7824-7840. https://doi.org/10.3748/wjg.v22.i34.7824 PMid:27678366 PMCid:PMC5016383
35. Rekomendatsiyi Yevropeyskoi asotsiatsiyi z doslidzhennya pechinky (EASL) shchodo likuvannya gepatytu C [Clinical Practical Guidelines of European Association for the Study of the Liver (EASL) on the management of therapy for chronic hepatitis C.] [Internet]. Zhurnal z gepatologiyi. 2018. Available from: https://phc.org.ua/sites/default/files/users/user90/%D0%A3%D0%9A%D0%A0%20EASL%20%D0%93%D0%B5%D0%BF%D0%B0%D1%82%D0%B8%D1%82%20%D0%A1%202018.pdf. [Ukrainian]
36. Cacoub P, Comarmond C. New insights into HCV-related rheumatologic disorders: A review. J Adv Res. 2017; 8(2): 89-97. https://doi.org/10.1016/j.jare.2016.07.005 PMid:28149645 PMCid:PMC5272935
37. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer. 2014; 135(5) :1119-1126. https://doi.org/10.1002/ijc.28753 PMid:24482200
38. Lonardo A, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 2014; 20(23): 7089-7103. https://doi.org/10.3748/wjg.v20.i23.7089 PMid:24966582 PMCid:PMC4064057
39. Negro F, Esmat G. Extrahepatic manifestations in hepatitis C virus infection. Journal of Advanced Research. 2017; 8(2): 85-87. https://doi.org/10.1016/j.jare.2016.08.004 PMid:28149644 PMCid:PMC5272942
40. Guaraldi G, Lonardo A, Maia L, Palella FJ Jr. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS. 2017; 31 Suppl 2: S147-S156. https://doi.org/10.1097/QAD.0000000000001483 PMid:28471945
41. Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005; 42(6): 799-805.https://doi.org/10.1016/j.jhep.2005.01.022 PMid:15973779
42. Sukhoruk AA, Gerasimova OA, Esaulenko EV. Tsirroz pecheni kak iskhod khronicheskogo gepatita S [Liver cirrhosis as an outcome of chronic hepatitis C]. Zhurnal infektologii. 2014; 6(1): 67-71. [Russian]
43. Enaleeva DSh, Fazylov VKh, Sozinov AS. Khronicheskie virusnye gepatity V, S i D [Chronic viral hepatitis B, C and D]. MEDpress-inform. 2011: 464. [Russian]
44. Ryabichenko VV, Chemych MD. Kliniko-epidemiologichni osoblyvosti khronichnogo gepatytu S [Clinical and epidemiological features of chronic hepatitis C]. Infektsiyni khvoroby. 2014; 1: 12-16. [Ukrainian]
45. Zaytsev IA, Potiy VV, Kiriyenko VT. Vozmozhnye strategii realizatsii programmy VOZ po eliminatsii gepatita S v Ukraine k 2030 godu [Possible strategies for implementation of the WHO program on the elimination of hepatitis Cin Ukraine by 2030]. Gepatologiya. 2017; 4: 6-13. [Russian]
46. Fedorchenko SV, Antonyak SN. Rozpovsyudzhennya genotypiv i replykatyvna aktyvnist NSV u patsiyentiv iz koinfektsiyeyu HCV/HIV ta khvorykh na khronichnyi gepatyt S [Dissemination of genotypes and replicative activity of HCV-coinfected patients HCV/HIV and chronic hepatitis C patients]. Profilaktychna medytsyna. 2013; 3-4(21): 59-63. [Ukrainian]
47. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003; 38(3): 257-265. https://doi.org/10.1016/S0168-8278(02)00413-0
48. Zhdanov KV, Kozlov KV, Sukachev VS. Evolyutsiya protivovirusnoy terapii khronicheskikh gepatitov V, S i D [Evolution of antiviral treatment chronic for hepatitis B, C and D]. Zhurnal infektologii. 2009; 1(4): 23-35. [Russian]
49. Highleyman L. Liver fibrosis improves after successful treatment for hepatitis C. [Internet]. 2015. Available from: http://www.infohep.org/Liver-fibrosis-improves-after-successful-treatment-for-hepatitis- C/page/3018918/#:~:text=Liver%20fibrosis%20improves%20after%20successful%20treatment%20for%20hepatitis%20C,-Liz%20Highleyman&text=A%20majority%20of%20people%20with,Meeting%20in%20San%20Francisco%2C%20USA